Comparison · NCT00659438-27ee4deb
Vandetanib vs Placebo: PSA Response Rate
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Vandetanib vs Placebo: PSA Response Rate. Trial comparisons, record NCT00659438-27ee4deb. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00659438-27ee4deb
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0638 | 0.0219 | 0.172 | wilson | |
| Risk in group 2 | 0.104 | 0.0453 | 0.222 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0403 | -0.165 | 0.0825 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.613 | 0.155 | 2.42 | log | |
| Odds ratio, group 1 over group 2 | 0.586 | 0.132 | 2.61 | log | |
| Number needed to treat, for one fewer participant with the outcome on Vandetanib than on Placebo | 24.8 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Vandetanib | Bicalutamide 150mg + Vandetanib (ZD6474) 300mg | 3 | 47 | OG000 |
| Group 2 | Placebo | Bicalutamide 150mg + placebo | 5 | 48 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- PSA Response Rate
- Description
To investigate the effect of vandetanib on the PSA response rate. PSA response rate defined by the number of participants with a PSA decrease relative to baseline of at least 50%.~A minimum decrease of 2 ng/mL in absolute value and a confirmation on at least 2 consecutive occasions (at least 4 weeks apart) were requested.
- Time frame
- 4 months
- Population
Source ClinicalTrials.gov
Trial
- Title
- Efficacy and Safety of Zactima™ in Patients With Castration-refractory Metastatic Prostate Cancer
- NCT number
- NCT00659438
- Phases
- PHASE2
- Conditions
- Prostate Cancer
- Interventions
- ZD6474 (Vandetanib), Bicalutamide, Placebo
- Lead sponsor
- Genzyme, a Sanofi Company
- Results first posted
- 2012-07-18
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00659438?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00659438-27ee4deb